Current benign prostatic hyperplasia treatment: Impact on sexual function and management of related sexual adverse events

International Journal of Clinical Practice

Volumn 65, Issue 9, 2011, Pages 1005-1013

  Mirone, V ^a   Sessa, A ^b   Giuliano, F ^c   Berges, R ^d   Kirby, M ^e   Moncada, I ^f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Italian College of General Practitioners   (Italy)

^c RAYMOND POINCARÉ HOSPITAL   (France)

^d PAN Klinik am Neumarkt   (Germany)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f HOSPITAL LA ZARZUELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLIC GMP; DOXAZOSIN; DUTASTERIDE; ENDOTHELIN 1; FINASTERIDE; NITRIC OXIDE; PLACEBO; RHO KINASE; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; THIAZIDE DIURETIC AGENT;

AGE; ATHEROSCLEROSIS; AUTONOMIC DYSFUNCTION; COMORBIDITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE SEXUAL DYSFUNCTION; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SIDE EFFECT; SPERM; WEIGHT REDUCTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM DISEASES; CYCLIC GMP; DRUG COMBINATIONS; ENDOTHELIN-1; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITRIC OXIDE; PROSTATIC HYPERPLASIA; PROSTATISM; RHO-ASSOCIATED KINASES; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 80051885150     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02731.x     Document Type: Review

References (71)

1. Girman CJ, Jacobsen SJ, Guess HA, et al., Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510-5.
2. Oelke M, Bachmann A, Descazeaud A, et al., Guidelines on Conservative Treatment of Non-neurogenic Male LUTS. European Urology Association, 2010. (accessed January 2011).
3. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R, British Association of Urological Surgeons. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004; 93: 985-90. (Pubitemid 38758619)
4. McVary KT,. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12: S122-8.
5. Corona G, Lee DM, Forti G, et al., Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010; 7: 1362-80.
6. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB,. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460-3. (Pubitemid 30060493)
7. Blanker MH, Bosch JL, Groeneveld FP, et al., Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57: 763-8.
8. Gan M, Smit M, Dohle GR, Bosch JL, Bohnen A,. Determinants of ejaculatory dysfunction in a community-based longitudinal study. BJU Int 2007; 99: 1443-8. (Pubitemid 47164807)
9. Fourcade RO, Théret N, Taïeb C,. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European Countries. BJU Int 2008; 101: 1111-8. (Pubitemid 351502660)
10. Robertson C, Link CL, Onel E, et al., The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007; 99: 347-54. (Pubitemid 46103115)
11. Rosen RC, Seidman SN, Menza MA, et al., Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 2004; 16: 334-40. (Pubitemid 39273759)
12. AUA Practice Guidelines Committee. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research; 2006: 1-54. (accessed January 2011).
13. Giuliano F,. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006; 97 (Suppl. 2): 34-8. (Pubitemid 43356994)
14. Rosen RC,. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 2006; 16: 11-9. (Pubitemid 43041215)
15. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M, Perelman MA,. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry. Urology 2009; 73: 562-6.
16. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH,. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical 'Aging Male' symptoms? Results of the 'Cologne Male Survey'. Eur Urol 2003; 44: 588-94. (Pubitemid 37336515)
17. Rosen R, Altwein J, Boyle P, et al., Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003; 44: 637-49. (Pubitemid 37542920)
18. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP,. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 33-41.
19. Morant S, Bloomfield G, Vats V, Chapple C,. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med 2009; 6: 1103-10.
20. Aslan G, Cavus E, Karas H, Oner O, Duran F, Esen A,. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl 2006; 52: 155-62.
21. McVary KT,. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838-45. (Pubitemid 40745354)
22. Ehren I, Adolfsson J, Wiklund NP,. Nitric oxide synthase activity in the human urogenital tract. Urol Res 1994; 22: 287-90. (Pubitemid 24369382)
23. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H,. Effects of nitric oxide on human and canine prostates. Urology 1995; 45: 440-6.
24. Uckert S, Sormes M, Kedia G, et al., Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526-30. (Pubitemid 351374723)
25. Filippi S, Morelli A, Sandner P, et al., Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-29.
26. Bittencourt JA, Tano T, Gajar SA, et al., Relaxant effects of sildenafil on the human isolated bladder neck. Urology 2009; 73: 427-30.
27. Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM,. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998; 53: 467-74.
28. Gur S, Kadowitz PJ, Hellstrom WJG,. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction. Implications for sexual function. Drugs 2008; 68: 209-29.
29. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S,. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170: 2517-22. (Pubitemid 37414047)
30. Chang S, Hypolite JA, Zderic SA, Wein AJ, Chacko S, Disanto ME,. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1124-30. (Pubitemid 41397062)
31. Hammarsten J, Hogstedt B, Holthius N, Mellstrom D,. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157-62. (Pubitemid 128545860)
32. Alberti KG, Zimmet P, Shaw J,. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62. (Pubitemid 41338752)
33. Kupelian V, McVary KT, Kaplan SA, et al., Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009; 182: 616-24.
34. Kirby MG, Wagg A, Cardozo L, et al., Overactive bladder: is there a link to the metabolic syndrome in men? Neurourol Urodyn 2010; 29: 1360-4.
35. Straznicky NE, Eikelis N, Lambert EA, Esler MD,. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep 2008; 10: 440-7.
36. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE,. Growth of the prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51: 99-107. (Pubitemid 24179226)
37. Golomb E, Rosenzweig N, Ellam R, Abramovici A,. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000; 21: 58-64. (Pubitemid 30069082)
38. Persson K, Pandita RK, Spitsbergen JM, Steers WD, Tuttle JB, Andersson KE,. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998; 275: R1366-73.
39. Behr-Roussel D, Chamiot-Clerc P, Bernabe J, et al., Erectile dysfunction in spontaneously hypertensive rats: pathophysiological mechanisms. Am J Physiol Regul Integr Comp Physiol 2003; 284: R682-8. (Pubitemid 36342801)
40. McVary KT, Rademaker A, Lloyd GL, Gann P,. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2005; 174: 1327-33. (Pubitemid 41318722)
41. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ,. Age related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol 1998; 82 (Suppl. 1): 26-33.
42. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ,. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol 1999; 161: 1626-35. (Pubitemid 29420853)
43. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM,. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 2001; 165: 1019-26. (Pubitemid 32156342)
44. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB,. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003; 170: 659-63. (Pubitemid 36870279)
45. Roehrborn CG, Siami P, Barkin J, et al., The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-31.
46. McConnell JD, Roehrborn CG, Bautista OM, et al., The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98. (Pubitemid 37542987)
47. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G,. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41. (Pubitemid 35292169)
48. McConnell JD, Bruskewitz R, Walsh P, et al., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63. (Pubitemid 28114643)
49. Hellstrom WJG, Giuliano F, Rosen RC,. Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment. Urology 2009; 74: 15-21.
50. Wessells H, Roy J, Bannow J, et al., Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61: 579-84. (Pubitemid 36294195)
51. Schulman C, Pommerville P, Höfner K, Wachs B,. Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int 2005; 97: 73-80.
52. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G,. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181: 2634-40.
53. Andersson KE, Gratzke C,. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007; 4: 368-78. (Pubitemid 47307620)
54. Roehrborn CG,. Efficacy of α-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 2009; 11 (Suppl. 1): S1-8.
55. Wilt TJ, MacDonald R, Rutks I,. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003; 1: CD002081.
56. Lepor H, for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 901-6. (Pubitemid 28240846)
57. Seftel S, Rosen R, Kuritzky L,. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007; 19: 386-92. (Pubitemid 47026079)
58. Vallancien G, Emberton M, Harving N, van Moorselaar RJ, Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257-61. (Pubitemid 36576765)
59. Mondaini N, Gontero P, Giubilei G, et al., Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007; 4: 1708-12. (Pubitemid 47616863)
60. Silvestri A, Galetta P, Cerquetani E, et al., Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928-32. (Pubitemid 37322702)
61. Barsky AJ, Saintfort R, Rogers P, Borus JF,. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002; 287: 622-7. (Pubitemid 34252015)
62. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A,. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30. (Pubitemid 27246947)
63. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM,. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-26. (Pubitemid 30052683)
64. Rosen RC, Catania JA, Althof SE, et al., Development and validation of four-item version of the Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology 2007; 69: 805-9. (Pubitemid 46670268)
65. Marquis P, Marrel A,. Reproducibility and clinical and concurrent validity of the MSF-4: a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia. Value Health 2001; 4: 335-43. (Pubitemid 32756818)
66. Kaplan SA,. Reproducibility and clinical and concurrent validity of the MSF-4: a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia. J Urol 2002; 168: 1661-2.
67. Düsing R,. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29-34. (Pubitemid 38112142)
68. Jackson G,. The importance of risk factor reduction in erectile dysfunction. Curr Urol Rep 2007; 8: 463-6. (Pubitemid 350144524)
69. Esposito K, Ciotola M, Giugliano F, et al., Effects of intensive lifestyle changes on erectile dysfunction in men. J Sex Med 2009; 6: 243-50.
70. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E,. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236-44.
71. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L,. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010; 75: 1452-8.